Let us advance cancer therapies together
Join us at AACR 2025 to explore how Champions Oncology’s in vivo, ex vivo platforms, and clinical specialty testing services can fast-track your cancer drug development.
Champions' team of expert scientists are presenting 17 novel research posters at the 2025 annual meeting. Discover how our innovative oncology services portfolio can support your research and upcoming clinical trials. To plan your meeting, you can download and save each poster's schedule to your calendar. The posters will be available for download after the conference.
Sunday - April 27, 2025
⏱︎ 2:00PM - 5:00 PM 📃Poster section 38 / Board 29
#928: Advancing CAR-Ts and anti-immunosuppressive therapy development: Immunosuppressive TME 3D co-culture platform grounded on a fully characterized PDX tumor Bank
Monday - April 28, 2025
⏱︎ 9 AM - 12:00 PM 📃Poster section 3 / Board 20
#1287: Clinical relevance and translatability of NSCLC patient-derived xenograft (PDX) models for evaluating cMET-targeted therapies
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 1 / Board 12
#1228: High throughput phenotyping and drug discovery using the TumorGraft3D co-culture platform and flow cytometry
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 24 / Board 13
#1827: Investigating the efficacy of 177-Lu therapeutics in a series of Castrate Resistant Prostate Cancer PDX Models
⏱︎ 2:00 PM - 5:00 PM 📃Poster section 14 / Board 16
#2849: Comparative analysis of mutational signatures in TumorGraft PDX bank and TCGA dataset to improve patient tumor modeling
⏱︎ 2:00 PM - 5:00 PM 📃Poster section 47 / Board 16
#3717: A Digital Patient & Simulated Clinical Trial of Cytarabine Treatment
Tuesday - April 29, 2025
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 3 / Board 27
#3903: Multi-omics and histological assessment to identify patient-derived xenograft models of invasive lobular carcinoma
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 7 / Board 23
#4007: Building 3D ex vivo models as a powerful platform for anti-cancer drug and biomarker discovery
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 7 / Board 22
#4006: HER2-positive patient-derived xenograft organoids (PDXOs) as a novel preclinical tool to evaluate new therapies against HER2-driven cancers
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 7 / Board 9
#3993: High-throughput screening of clinically relevant patient-derived 3D cultures to inform on the efficacy of Antibody Drug Conjugate Payloads in 10 distinct cancer indications
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 4 / Board 24
#3931: Establishment of an orthotopic intracranial luciferase labelled patient-derived xenograft of glioblastoma in immunocompromised mice model
⏱︎ 2:00 PM - 5:00 PM 📃Poster section 45 / Board 22
#6275 Predicting clinical checkpoint inhibitor responses with TumorGraft3D PBMC co-culture
⏱︎ 2:00 PM - 5:00 PM 📃Poster section 19 / Board 3
#5567: Targeted immunotherapies in Multiple Myeloma: focus on flow cytometry markers and therapeutic implications
Wednesday - April 30, 2025
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 20 / Board 12
#6851: An integrated preclinical platform for Antibody-Drug Conjugate development
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 38 / Board 28
#7281: Leveraging the tumor microenvironment (TME) atlas to identify the best PDX model for pre-clinical testing of TME targeting agents
⏱︎ 9:00 AM - 12:00 PM 📃Poster section 38 / Board 29
#7282: Development of an HLA-matched humanized immune system mouse model with primary AML patient samples for immunotherapy testing
